CyberKnife Cure Rates for Non-Metastatic Prostate Cancer: For high-risk prostate cancer, specifically a Gleason score of 8 or 9, CyberKnife—a form of stereotactic body radiation therapy (SBRT)—is considered a viable and effective treatment, typically in combination with hormone therapy.
While CyberKnife has historically been used for lower-risk and moderate disease, recent clinical data and ongoing studies support its use for high-risk patients, often combined with other therapies to improve outcomes.
CyberKnife for high-risk prostate cancer:
CyberKnife works by delivering a very precise, high dose of radiation to the tumor in just four to five sessions.
Key features include:
Precision: Using a robotic arm and real-time image guidance, the system continuously tracks the tumor’s movement and adjusts the radiation beams to ensure sub-millimeter accuracy.
Effectiveness: In high-risk cases, a course of CyberKnife SBRT is usually combined with androgen deprivation therapy (ADT), which suppresses hormones that fuel prostate cancer growth.
Outcomes: Studies on SBRT for high-risk prostate cancer have shown favorable outcomes, with five-year biochemical progression-free survival rates exceeding 80% when combined with ADT.
Before making a decision on your treatment plan it is essential to discuss all available options and potential side effects with your medical team.
At CyberKnife Miami our team will perform a thorough evaluation, including considering your overall health, to determine if you are a candidate for CyberKnife SBRT, possibly combined with hormone therapy.
Contact the CyberKnife Center of Miami “The Beam of Life” at 305-279-2900.